Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers - PubMed
6 days ago
- #Medullary Thyroid Carcinoma
- #Calcitonin
- #MEN2A
- The study evaluates calcitonin (CTN) thresholds for predicting medullary thyroid carcinoma (MTC) and clinical response in MEN2A gene carriers.
- Retrospective analysis of 106 gene carriers from an Italian tertiary referral center (1993-2024) was conducted.
- Most common mutation was RET V804M (34.3%), followed by mutations at codon 634 (16.2%).
- 81.1% of patients had MTC, while 18.9% had C-cell hyperplasia (CCH) alone.
- MTC patients were older, with higher preoperative basal (bCTN) and stimulated (sCTN) calcitonin levels.
- bCTN > 12.60 ng/L identified MTC with 94.4% sensitivity and 74.3% specificity.
- Incomplete response (IR) was observed in 22.9% of patients over a median follow-up of 6.8 years.
- bCTN < 28.25 ng/L predicted excellent response (ER) with 95.5% specificity and 76.8% sensitivity.
- Multivariate analysis identified bCTN < 28.25 ng/L and absence of lymph node metastases as independent predictors of ER.
- Gene carriers with preoperative bCTN between 12.6 and 28.3 ng/L have high probability of complete remission post-surgery.